<DOC>
	<DOCNO>NCT02580201</DOCNO>
	<brief_summary>The purpose study assess safety ( serious adverse event [ SAEs ] ) , severe adverse event [ AEs ] ( grade 3 accord CTCAE 4.03 ) one dose SABIN tOPV 1-5 year-old child three dos SABIN tOPV 6 week-old infant , immunogenicity ( seroprotection rate 3 serotypes ) 28 day three dos SABIN tOPV vaccine-naïve infant .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity tOPV 1 5 Years 6 Weeks Age</brief_title>
	<detailed_description>This single center , open study child ( age 1 5 year ) vaccine-naïve infant , follow : 50 OPV-vaccinated child age 1 5 year receive 1 dose tOPV ( Group 1 ) ; 104 vaccine-naïve infant receive 3 dos tOPV administer 28 day apart ( Group 2 )</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Age : Group 1 Children age 15 year , previously vaccinate ≥ 3 dos OPV . Group 2 Infants age 6 week ( 7 +14 day ) previous polio vaccination . 2 . Healthy without obvious medical condition preclude subject study establish medical history physical examination . 3 . Written inform consent obtain 1 2 parent legal guardian per Dominican Republic regulation . 1 . Previous Vaccinations : Group 1 : Previous vaccination poliovirus outside national immunization schedule vaccine previous 4 week . Group 2 : Any vaccination poliovirus 2 . Group 2 : Infants birth weight ( BW ) &lt; 2,500 gm . 3 . Any confirmed suspected immunosuppressive know immunodeficient condition include human immunodeficiency virus ( HIV ) infection . 4 . Family history congenital hereditary immunodeficiency . 5 . Major congenital defect serious uncontrolled chronic illness ( neurologic , pulmonary , gastrointestinal , hepatic , renal , endocrine ) . 6 . Known allergy component study vaccine antibiotic . 7 . Uncontrolled coagulopathy blood disorder contraindicate intramuscular injection . 8 . Administration immunoglobulins and/or blood product since birth plan administration study period . 9 . Acute severe febrile illness day vaccination deem Investigator contraindication vaccination ( child include late time within age window in/exclusion criterion meet ) . 10 . Member subject 's household ( live house apartment unit ) receive OPV last 3 month , schedule receive OPV study period . 11 . Subject , opinion Investigator , unlikely comply protocol inappropriate include study safety benefitrisk ratio subject .</criteria>
	<gender>All</gender>
	<minimum_age>5 Weeks</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>